18:42 , Dec 22, 2017 |  BC Week In Review  |  Company News

Millendo to acquire Alize, gains Prader-Willi candidate

Millendo Therapeutics Inc. (Ann Arbor, Mich.) acquired Alizé Pharma S.A.S. (Lyon, France), an Alizé Pharma (Lyon, France) company, in a stock deal. Financial terms were not disclosed. The former Alizé Pharma S.A.S. facilities will maintain its...
03:45 , Apr 7, 2017 |  BC Innovations  |  Strategy

Pushing for progress in Prader-Willi

In the wake of the 2015 clinical failure of Zafgen Inc.’s subcutaneous beloranib for obesity in Prader-Willi syndrome patients, the Foundation for Prader-Willi Research (FPWR) last year launched a five-year, $26 million strategic research plan...
22:30 , Mar 16, 2017 |  BC Innovations  |  Targets & Mechanisms

Bone appétit!

Last week’s Nature publication of a hormone secreted by bone that suppresses appetite and can curb weight gain not only adds to the emerging picture of bone as a player in the endocrine system but...
07:00 , May 23, 2016 |  BC Week In Review  |  Company News

Alize Pharma, Jazz Pharmaceuticals deal

Jazz acquired Alize’s Alize Pharma II S.A.S. company for EUR8 million ($9.1 million) in cash up front, plus up to EUR10 million ($11.3 million) in cash in potential regulatory milestones. Alize Pharma II’s lead product,...
07:00 , May 2, 2016 |  BC Week In Review  |  Clinical News

AZP-531: Additional Phase II data

Top-line data from a double-blind, European Phase II trial in 47 patients with Prader-Willi syndrome and evidence of hyperphagia showed that once-daily subcutaneous AZP-531 for 2 weeks significantly improved Hyperphagia Questionnaire Hyperphagic Severity domain score...
01:14 , Apr 27, 2016 |  BC Extra  |  Clinical News

Alize reports Phase II Prader-Willi data

Alize Pharma S.A.S. (Lyon, France) said once-daily subcutaneous AZP-531 for two weeks led to significant improvements in hyperphagia-related behavior vs. placebo in a European Phase II trial to treat Prader-Willi syndrome. The unacylated ghrelin analog...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

AZP-531: Phase IIa started

Alize began a double-blind, placebo-controlled, European Phase IIa trial to evaluate 2, 3 and 4 mg subcutaneous AZP-531 given once daily for 2 weeks in up to 40 patients. Alize Pharma, Lyon, France   Product: ...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Financial News

Alize Pharma completes venture financing

Alize Pharma, Lyon, France   Business: Endocrine/Metabolic   Date completed: 2015-03-17   Type: Venture financing   Raised: EUR1.8 million ($1.9 million)   Investors: Sofimac; Octalfa S.A.S.; Sham; Rhone Alpes Creation; Credit Agricole; CEMA Inc.; TAB Consulting   Note: Alize Pharma’s Alize...
07:00 , Mar 23, 2015 |  BioCentury  |  Finance

Alize's assets

French biotech Alize Pharma S.A.S. is employing an asset-centric model similar to those used by Atlas Venture or Index Ventures to maximize both capital efficiency and the attractiveness of the assets in its pipeline to...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Clinical News

AZP-531: Interim Phase I data

Interim data from a 3-part, double-blind, placebo-controlled, U.K. Phase Ia/Ib trial showed that subcutaneous AZP-531 was well tolerated as single ascending doses in 44 healthy volunteers and as once-daily ascending doses for 14 days in...